GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Burzynski Research Institute Inc (OTCPK:BZYR) » Definitions » 3-Year RORE %

Burzynski Research Institute (Burzynski Research Institute) 3-Year RORE % : 5.26% (As of Nov. 2023)


View and export this data going back to . Start your Free Trial

What is Burzynski Research Institute 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Burzynski Research Institute's 3-Year RORE % for the quarter that ended in Nov. 2023 was 5.26%.

The industry rank for Burzynski Research Institute's 3-Year RORE % or its related term are showing as below:

BZYR's 3-Year RORE % is ranked better than
66.29% of 1400 companies
in the Biotechnology industry
Industry Median: -7.59 vs BZYR: 5.26

Burzynski Research Institute 3-Year RORE % Historical Data

The historical data trend for Burzynski Research Institute's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burzynski Research Institute 3-Year RORE % Chart

Burzynski Research Institute Annual Data
Trend Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.68 3.03 -16.67 -20.83 -5.26

Burzynski Research Institute Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.26 -5.26 - - 5.26

Competitive Comparison of Burzynski Research Institute's 3-Year RORE %

For the Biotechnology subindustry, Burzynski Research Institute's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Burzynski Research Institute's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Burzynski Research Institute's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Burzynski Research Institute's 3-Year RORE % falls into.



Burzynski Research Institute 3-Year RORE % Calculation

Burzynski Research Institute's 3-Year RORE % for the quarter that ended in Nov. 2023 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.007--0.006 )/( -0.019-0 )
=-0.001/-0.019
=5.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Nov. 2023 and 3-year before.


Burzynski Research Institute  (OTCPK:BZYR) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Burzynski Research Institute 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Burzynski Research Institute's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Burzynski Research Institute (Burzynski Research Institute) Business Description

Traded in Other Exchanges
N/A
Address
9432 Katy Freeway, Houston, TX, USA, 77055
Burzynski Research Institute Inc engages in the research, production, marketing, promotion, and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name Antineoplastons. Antineoplastons are used in the treatment of human cancer. Its pipeline development programs of the company include clinical trials for the treatment of a wide variety of cancers using only a combination of Antineoplastons A10 and AS2-1.
Executives
Monika Szopa-paszkowiak director 9432 KATY FWY #200, HOUSTON TX 77055
Frederick Richard Schiff director 9432 KATY FREEWAY, HOUSTON TX 77055
Barbara Burzynski director, 10 percent owner 9432 KATY FREEWAY, HOUSTON TX 77055
Carlton Hazlewood director 9432 KATY FREEWAY, HOUSTON TX 77055
Patryk Goscianski officer: Secretary and Treasurer 9432 KATY FREEWAY, HOUSTON TX 77055
Gregory Burzynski director 9432 KATY FREEWAY, HOUSTON TX 77055
Tomasz Janicki officer: VP of Clinical Trials 9432 KATY FREEWAY, HOUSTON TX 77055
Michael Driscoll director 9432 KATY FREEWAY, HOUSTON TX 77055
Stanislaw Burzynski director, 10 percent owner, officer: President 9432 KATY FREEWAY, HOUSTON TX 77055
Dudley Reece Anderson officer: Chief Financial Officer 9432 OLD KATY RD., SUITE 200, HOUSTON TX 77055

Burzynski Research Institute (Burzynski Research Institute) Headlines

No Headlines